{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:35:45Z","timestamp":1792449345395,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bmc.2025.118127","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:27:35Z","timestamp":1740137255000},"page":"118127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis and biological activity of 8-hydroxy modified urolithin A derivatives as phosphodiesterase type II (PDE2) inhibitors"],"prefix":"10.1016","volume":"121","author":[{"given":"Feng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118127_b0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1586\/14737175.2015.995637","article-title":"Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future","volume":"15","author":"Hampel","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.bmc.2025.118127_b0010","first-page":"140","article-title":"The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome","volume":"4","author":"Portis","year":"2012","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"10.1016\/j.bmc.2025.118127_b0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","article-title":"The many faces of CREB","volume":"28","author":"Carlezon","year":"2005","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bmc.2025.118127_b0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.expneurol.2013.09.001","article-title":"Presenilins regulate the cellular activity of ryanodine receptors differentially through isotype-specific N-terminal cysteines","volume":"250","author":"Payne","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bmc.2025.118127_b0025","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","article-title":"Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease","volume":"61","author":"Wu","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118127_b0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","article-title":"Multi-target design strategies for the improved treatment of Alzheimer's disease","volume":"176","author":"Zhang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118127_b0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/cns.12863","article-title":"The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor","volume":"24","author":"Liu","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.bmc.2025.118127_b0040","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","article-title":"Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance","volume":"47","author":"Boess","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmc.2025.118127_b0045","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainres.2008.02.108","article-title":"The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging","volume":"1216","author":"Domek-\u0141opaci\u0144ska","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.bmc.2025.118127_b0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00213-015-4129-1","article-title":"Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice","volume":"233","author":"Lueptow","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bmc.2025.118127_b0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","article-title":"Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801","volume":"236","author":"Reneerkens","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bmc.2025.118127_b0060","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1021\/jp8082612","article-title":"Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation","volume":"113","author":"Hamza","year":"2009","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.bmc.2025.118127_b0065","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/270418","article-title":"Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far","volume":"2013","author":"Esp\u00edn","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.bmc.2025.118127_b0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/mnfr.201500901","article-title":"Urolithins, the rescue of \u201cold\u201d metabolites to understand a \u201cnew\u201d concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status","volume":"61","author":"Tom\u00e1s-Barber\u00e1n","year":"2017","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.bmc.2025.118127_b0075","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1021\/jf100315d","article-title":"Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy","volume":"58","author":"Gonz\u00e1lez-Barrio","year":"2010","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.bmc.2025.118127_b0080","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1126\/scitranslmed.abb0319","article-title":"Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy","volume":"13","author":"Luan","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2025.118127_b0085","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/gerona\/glq135","article-title":"A vascular theory of aging","volume":"65","author":"Le Couteur","year":"2010","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.bmc.2025.118127_b0090","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bbrc.2017.03.119","article-title":"Urolithin A alleviates myocardial ischemia\/reperfusion injury via PI3K\/Akt pathway","volume":"486","author":"Tang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2025.118127_b0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.pharep.2017.04.020","article-title":"Urolithin A shows anti-atherosclerotic activity via activation of class B scavenger receptor and activation of Nef2 signaling pathway","volume":"70","author":"Cui","year":"2018","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bmc.2025.118127_b0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-017-0561-3","article-title":"In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats","volume":"16","author":"Savi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.bmc.2025.118127_b0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41593-018-0332-9","article-title":"Mitophagy inhibits amyloid-\u03b2 and tau pathology and reverses cognitive deficits in models of Alzheimer's disease","volume":"22","author":"Fang","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bmc.2025.118127_b0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12974-019-1450-3","article-title":"Urolithin A attenuates memory impairment and neuroinflammation in APP\/PS1 mice","volume":"16","author":"Gong","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.bmc.2025.118127_b0115","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.2015.3058","article-title":"Acute stroke intervention: a systematic review","volume":"313","author":"Prabhakaran","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bmc.2025.118127_b0120","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/cns.13136","article-title":"Urolithin A-activated autophagy but not mitophagy protects against ischemic neuronal injury by inhibiting ER stress in vitro and in vivo","volume":"25","author":"Ahsan","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.bmc.2025.118127_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103227","article-title":"Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor","volume":"64","author":"Shen","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bmc.2025.118127_b0130","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1039\/C9FO01332F","article-title":"Urolithin A targets the PI3K\/Akt\/NF-\u03baB pathways and prevents IL-1\u03b2-induced inflammatory response in human osteoarthritis: in vitro and in vivo studies","volume":"10","author":"Fu","year":"2019","journal-title":"Food Funct"},{"key":"10.1016\/j.bmc.2025.118127_b0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41467-018-07859-7","article-title":"Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway","volume":"10","author":"Singh","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118127_b0140","doi-asserted-by":"crossref","first-page":"F1255","DOI":"10.1152\/ajprenal.00346.2019","article-title":"Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI","volume":"317","author":"Zou","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bmc.2025.118127_b0145","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/oby.22404","article-title":"Urolithin A, a Gut Metabolite, Improves Insulin Sensitivity Through Augmentation of Mitochondrial Function and Biogenesis","volume":"27","author":"Toney","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.bmc.2025.118127_b0150","article-title":"Ellagic Acid and Its Microbial Metabolite Urolithin A Alleviate Diet-Induced Insulin Resistance in Mice","volume":"64","author":"Yang","year":"2020","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.bmc.2025.118127_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2019.112479","article-title":"Pancreas protective effects of Urolithin A on type 2 diabetic mice induced by high fat and streptozotocin via regulating autophagy and AKT\/mTOR signaling pathway","volume":"250","author":"Tuohetaerbaike","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bmc.2025.118127_b0160","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/jn\/136.10.2481","article-title":"Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours","volume":"136","author":"Seeram","year":"2006","journal-title":"J Nutr"},{"key":"10.1016\/j.bmc.2025.118127_b0165","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1021\/acschemneuro.5b00051","article-title":"Fate of microbial metabolites of dietary polyphenols in rats: is the brain their target destination","volume":"6","author":"Gasperotti","year":"2015","journal-title":"ACS Chem Nerosci"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:29:05Z","timestamp":1777602545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"alternative-id":["S0968089625000689"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118127","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological activity of 8-hydroxy modified urolithin A derivatives as phosphodiesterase type II (PDE2) inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118127"}}